Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Revised Quality Metrics Program: Voluntary Now, Mandatory Later

Executive Summary

US FDA will establish mandatory quality metrics reporting through a formal rulemaking process that could take years. Meanwhile, a revised draft guidance lays out plans for voluntary quality metrics reporting that could begin by January 2018.


Related Content

FDA Proposes To Rely On Industry-Driven Consensus Quality Standards In New Drug Reviews
The Next New Thing In FDA Inspections: Poor Root Cause Investigations
FDA Warns Apotex Management To Demand Quality, Meet Specs
FDA Resumes Quality Metrics Effort With Feedback And Site Visit Initiatives
US FDA Quality Metrics Initiative Continues Moving Forward … Quietly
FDA's Kopcha Presses Ahead On Quality Metrics Despite Industry Pushback
US FDA And OMB Should ‘Pause’ Billion-Dollar Quality Metrics Program, Industry Groups Say
FDA Builds Quality Dashboard To Focus CMC Reviews And Inspections On Greatest Risks
FDA Quality Metrics Proposal Sparks Objections, Disarray
FDA’s Quality Metrics Proposal Poses Challenges, Including 'Gaming,' Cost





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts